EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Multi‐Omics‐Enabled Precision Strategies for Overcoming CAR ‐T Therapy Limitations in Gastrointestinal Malignancies

Ke Su, Zunyuan Tan, Han Li, Kai You, Susu Xiao, Haiqing Chen, Danyang Li, Xin Liu, Xinrui Du, Jiaxin Hu iD, Kun He, Yantian Xu und 2 weitere

BioFactors · 2026-09 · 52 (5)

DOI: 10.1002/biof.70150 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioFactors, online erschienen am 09.09.2026. Verfasst von Ke Su und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China. Hauptthemen laut MEDLINE: Gastrointestinal Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health Commission of the People's Republic of China and the National Science and Technology Major Project for the Prevention and Treatment of Cancer,….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal malignancies, including gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic ductal adenocarcinoma, remain major causes of cancer‐related morbidity and mortality worldwide. Although chimeric antigen receptor T‐cell (CAR‐T) therapy has revolutionized the treatment of hematologic malignancies, its efficacy in gastrointestinal solid tumors remains limited by antigen heterogeneity, insufficient trafficking and infiltration, immunosuppressive tumor microenvironments, on‐target off‐tumor toxicity, and adaptive resistance. In this review, we summarize the current landscape of CAR‐T therapy in gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer, with a focus on representative target antigens and emerging biomarker strategies. We further discuss two major categories of biomarkers: target antigen‐related biomarkers and conventional dynamic biomarkers, including serum tumor markers, cytokine changes, CAR‐T expansion kinetics, and antigen‐loss monitoring. In addition, we highlight how single‐cell ribonucleic acid sequencing and spatial transcriptomics provide complementary insights into cellular states, immune exhaustion, stromal barriers, and spatially restricted immune exclusion. By integrating these multi‐omics approaches with biomarker‐guided patient stratification and next‐generation CAR‐T engineering, gastrointestinal solid tumor CAR‐T therapy may evolve from empirical optimization toward mechanism‐driven and precision‐guided clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansMultiomicsBiomarkers, TumorTumor MicroenvironmentPrecision MedicineLiver NeoplasmsAnimalsPancreatic Neoplasms

Stichwörter der Autor:innen

biomarkerchimeric antigen receptor T‐cell therapygastrointestinal malignanciesprecision oncologysingle‐cell ribonucleic acid sequencingspatial transcriptomics

Substanzen

Biomarkers, TumorReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China.
  • Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
  • School of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou, China.
  • Luzhou Key Laboratory of Interdisciplinary Science in Cancer Prevention and Treatment Integrating Chinese and Western Medicine, Luzhou, Sichuan, China.
  • Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
  • School of Clinical Medical, Southwest Medical University, Luzhou, China.

ORCID-Profile: Jiaxin Hu, Yunwei Han

Förderung

  • National Health Commission of the People's Republic of China and the National Science and Technology Major Project for the Prevention and Treatment of Cancer,…

Zitieren

APA

Su, K., Tan, Z., Li, H., You, K., Xiao, S., Chen, H., Li, D., Liu, X., Du, X., Hu, J., He, K., Xu, Y., Chen, J., & Han, Y. (2026). Multi‐Omics‐Enabled Precision Strategies for Overcoming CAR ‐T Therapy Limitations in Gastrointestinal Malignancies. BioFactors, 52(5). https://doi.org/10.1002/biof.70150

Vancouver

Su K, Tan Z, Li H, You K, Xiao S, Chen H, et al. Multi‐Omics‐Enabled Precision Strategies for Overcoming CAR ‐T Therapy Limitations in Gastrointestinal Malignancies. BioFactors. 2026;52(5). doi:10.1002/biof.70150

BibTeX
@article{Su2026,
  author = {Su, Ke and Tan, Zunyuan and Li, Han and You, Kai and Xiao, Susu and Chen, Haiqing and Li, Danyang and Liu, Xin and Du, Xinrui and Hu, Jiaxin and He, Kun and Xu, Yantian and Chen, Jian and Han, Yunwei},
  title = {Multi‐Omics‐Enabled Precision Strategies for Overcoming CAR ‐T Therapy Limitations in Gastrointestinal Malignancies},
  journal = {BioFactors},
  year = {2026},
  volume = {52},
  number = {5},
  doi = {10.1002/biof.70150}
}
Kostenlos starten →